In the management of locally advanced prostate cancer, bicalutamide monotherapy (150 mg) has definite benefits in terms of quality of life parameters like sexual interest and physical capacity which may make it an alternative to castration. Also when used as an adjuvant to standard care in the management of locally advanced prostate cancer, bicalutamide 150 mg may provide survival benefits. The given slide set provides information on the role of bicalutamide monotherapy in the management of locally advanced prostate cancer.